12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Abstral fentanyl regulatory update

ProStrakan reported that FDA said it will not meet the expected PDUFA date in early September for an NDA for Abstral fentanyl to treat breakthrough cancer pain. ProStrakan said the delay was due to ongoing discussions with the agency...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >